Compare TNET & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | NTLA |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2000 | 2016 |
| Metric | TNET | NTLA |
|---|---|---|
| Price | $36.12 | $12.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $65.80 | $20.45 |
| AVG Volume (30 Days) | 692.0K | ★ 3.6M |
| Earning Date | 05-15-2026 | 05-21-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $5,010,000,000.00 | $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | $73.07 |
| P/E Ratio | $11.31 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $33.67 | $5.90 |
| 52 Week High | $88.56 | $28.24 |
| Indicator | TNET | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 47.69 |
| Support Level | $33.67 | $10.44 |
| Resistance Level | $63.28 | $15.06 |
| Average True Range (ATR) | 1.97 | 0.95 |
| MACD | 0.57 | -0.12 |
| Stochastic Oscillator | 43.37 | 12.08 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company providesits services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.